Sanofi Forms Partnership With UMass Boston With $1 Million Support Of Student Success Program For STEM Education

Sanofi and its Cambridge-based biotechnology company, Genzyme, today announced a new partnership and $1 million gift to support student success programs in the University of Massachusetts Boston’s College of Science and Mathematics (CSM). The announcement of the gift was made at the opening of Sanofi’s new R&D facility at 640 Memorial Drive in Cambridge, which will be focused on cancer research.

“We thank and recognize Sanofi and Genzyme for sharing our vision for student success in science, technology, engineering, and mathematics (STEM) and for their partnership with UMass Boston students and the future of Greater Boston,” said Chancellor J. Keith Motley. “Supporting the Commonwealth's goal of continued leadership in scientific and technological innovation, CSM is providing its students with an outstanding academic experience that enhances their prospects for careers in STEM fields. This investment in UMass Boston students by Genzyme and Sanofi, which extends an existing partnership between UMass and these companies, represents an outstanding example of how a partnership between a public higher education institution and a major corporation can have a significant impact on developing a vibrant STEM workforce.”

Genzyme and Sanofi target their philanthropic giving toward areas of need in communities, with particular focus on science and education, including organizations that foster the next generation of diverse STEM leaders. The College of Science and Mathematics has developed a highly successful program for advancing student success in STEM majors. This program revamped advising, academic support, and orientation, and developed a learning community program as the centerpiece of this strategy. Retention in the program is more than 15 points above the college’s preexisting levels, with large increases of students remaining in STEM majors.

“This partnership means that together, we can make a major contribution to sustaining and enhancing the local R&D ecosystem and supporting our collective future by ensuring a steady supply of young people with advanced training and education,” said Christopher Viehbacher, Chief Executive Officer, Sanofi. “By supporting a vibrant life sciences community, we are also laying the foundation for the research that will drive future innovations for patients.”

If you liked this article you might like

With Eyes on Solar Eclipse, Wall Street Stumbles Yet Again

Renewed Speculation of ECB Tightening Boosts the Euro

European Banks Stocks Rebound as Investors Put Risk Bank Into Play